BR Biopharma (NASDAQ:BRBI) Trading Down 0.9% – Should You Sell?

BR Biopharma, Inc. (NASDAQ:BRBI)’s stock price fell 0.9% on Wednesday . The stock traded as low as $11.67 and last traded at $11.6490. 2,955 shares were traded during trading, an increase of 141% from the average session volume of 1,225 shares. The stock had previously closed at $11.75.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of BR Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

BR Biopharma Stock Performance

The company’s 50-day simple moving average is $14.06.

BR Biopharma (NASDAQ:BRBI) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.09 earnings per share (EPS) for the quarter. The company had revenue of $25.95 million during the quarter.

BR Biopharma Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 5th. Shareholders of record on Tuesday, May 19th were issued a dividend of $0.147 per share. The ex-dividend date was Tuesday, May 19th. This represents a $0.59 dividend on an annualized basis and a yield of 4.9%.

Institutional Trading of BR Biopharma

An institutional investor recently bought a new position in BR Biopharma stock. Acuitas Investments LLC bought a new position in shares of BR Biopharma, Inc. (NASDAQ:BRBI) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma makes up approximately 3.2% of Acuitas Investments LLC’s portfolio, making the stock its 7th largest position.

BR Biopharma Company Profile

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.